Key Insights• According to the research report, "Germany EPA & DHA Market Outlook, 2031," published by Actual Market Research, the Germany EPA & DHA Market is anticipated to grow at more than 5.99% CAGR from 2026 to 2031. The German EPA & DHA market is steadily expanding as the country faces one of Europe's most advanced demographic aging profiles and a persistent burden of cardiovascular disease, alongside strong consumer acceptance of food supplements sold through pharmacies and drugstores. According to Destatis, Germany's population stood at 83.5 million at the end of 2025, declining by 0.1% for the first time since 2020, while people aged 60 and older accounted for 31% of the population. Cardiovascular disease remains the leading cause of death, accounting for about 33.9% of all deaths in 2023. According to the German Heart Report Update 2025, coronary heart disease caused 119,795 deaths in 2023, including 43,839 deaths from acute myocardial infarction, while 538,675 hospital admissions were attributed primarily to coronary heart disease, making it the most common reason for hospitalization. Approximately 4.7 million people live with coronary heart disease in Germany, and the country's coronary mortality rate of 133.3 per 100,000 inhabitants remains high by European standards. The growing clinical burden is placing additional pressure on Germany's healthcare system and consumer health sector to strengthen access to EPA and DHA through supplements, fortified foods, infant nutrition, and clinical nutrition.• Germany's EPA & DHA market is characterized by a sophisticated ecosystem comprising pharmaceutical-grade omega-3 refiners, consumer health brands, drugstore chains, pharmacies, infant formula producers, and pet food manufacturers.

Germany is home to the pharmaceutical-grade omega-3 concentration facility of KD Pharma Group in Bexbach, Saarland; the group completed its acquisition of dsm-firmenich's Marine Lipids business, including the MEG-3 brand and facilities in Peru and Canada, in October 2024. Evonik, co-owner of the Veramaris algal oil joint venture with dsm-firmenich, completed a USD 200 million algal oil plant in Blair, Nebraska, in May 2025. Retail distribution is anchored by drugstore chains such as dm and Rossmann, whose private-label omega-3 ranges are among the highest-volume products in the market, alongside around 17,000 community pharmacies and fast-growing online pharmacies. Leading brands include Doppelherz (Queisser Pharma), Orthomol, Norsan, and Abtei.• Regulatory oversight for EPA and DHA products in Germany is shaped by European Union legislation implemented and enforced nationally. Food supplements are regulated under Directive 2002/46/EC, transposed through the German Food Supplements Ordinance (Nahrungsergänzungsmittelverordnung, NemV), and must be notified to the Federal Office of Consumer Protection and Food Safety (BVL) before marketing. Health claims for EPA and DHA are governed by Regulation (EC) No. 1924/2006 and the EU list of authorized claims under Regulation (EU) No. 432/2012, while infant and follow-on formula must contain DHA at 20–50 mg per 100 kcal under Delegated Regulation (EU) 2016/127.

The Federal Institute for Risk Assessment (BfR) provides scientific risk assessments, including recommended maximum levels for EPA and DHA in food supplements. Algal and krill oils require authorization under the EU Novel Food Regulation (EU) 2015/2283, with new algal oil strains continuing to be added to the Union list, including Schizochytrium sp. (CABIO-A-2) oil authorized in July 2024.Market Outlook• A defining characteristic of Germany's EPA & DHA market is the dual structure of high-volume drugstore private labels and premium pharmacy brands. Drugstore chains offer low-cost fish oil and algal oil capsules that have driven broad household penetration, while pharmacies and online pharmacies focus on high-concentration triglyceride oils, liquid fish oils, krill oil, and combination products positioned for cardiovascular, cognitive, eye, and joint health. German consumers place strong emphasis on purity, sustainability, and verified quality, encouraging adoption of MSC-certified fish oil, Friend of the Sea certification, IFOS testing, and fish-free algal alternatives. Simultaneously, the vegan and flexitarian trend in Germany, one of Europe's largest plant-based markets, is supporting rapid growth of algal EPA and DHA in supplements and fortified foods.• The market also reflects Germany's growing emphasis on prevention and healthy aging. The German Heart Report Update 2025, presented in September 2025, highlighted the need for stronger cardiovascular prevention given Germany's high coronary mortality relative to the EU average of 109.3 per 100,000 and Denmark's 56.7 per 100,000.

Cardiologists and pharmacists increasingly discuss omega-3 within broader lipid and lifestyle management. In infant nutrition, Destatis reported that 654,241 children were born in Germany in 2025, the lowest number since the postwar period, with the total fertility rate falling to 1.32 children per woman from 1.35 in 2024. The mandatory DHA requirement for infant formula ensures a stable baseline of demand for high-purity fish and algal DHA, even as volumes decline.Market DynamicsDriver: Rapid demographic aging and high cardiovascular disease burden supported by strong supplement cultureGermany's EPA & DHA market is primarily driven by demographic aging and the high prevalence of cardiovascular disease. People aged 60 and older represented 31% of the population at the end of 2025, according to Destatis. Coronary heart disease alone caused 119,795 deaths and 538,675 hospital admissions in 2023, and around 4.7 million Germans live with the condition, according to the German Heart Report Update 2025. Germany has one of Europe's most established supplement cultures, with omega-3 among the most widely purchased supplements in drugstores and pharmacies.

EU-authorized health claims enable EPA and DHA products to communicate benefits for normal heart function at 250 mg per day, maintenance of normal blood triglyceride levels at 2 g per day, and normal brain function and vision for DHA at 250 mg per day. As public awareness of cardiovascular prevention continues to grow, pharmacies and drugstores are witnessing sustained demand for high-quality EPA and DHA products.Challenge: Price competition from private labels, raw material volatility, and strict claim regulationOne of the principal challenges facing Germany's EPA & DHA market is intense price competition from drugstore and discounter private labels, which compresses margins for branded manufacturers. At the same time, raw material costs remain volatile. Peru's first 2026 north-central anchovy quota was set at 1,914,049 tonnes, approximately 36% lower than in 2025, following a coastal El Niño event, while the Antarctic krill fishery closed early on August 1, 2025, and again on August 12, 2026, after catches reached the 620,000 tonne trigger level. Additionally, the EU's strict health claims framework limits the claims that can be made for omega-3 products, and German courts and consumer organizations actively enforce compliance with claim and advertising rules. The absence of harmonized EU maximum levels for EPA and DHA in supplements also creates uncertainty, with national recommendations from the BfR influencing product formulation.

Together, these factors constrain pricing power and require continuous investment in compliance and quality differentiation.Trend: Expansion of algal omega-3 and sustainability-driven product innovationGermany is experiencing a significant shift toward plant-based and sustainability-certified omega-3 products supported by strong consumer demand for vegan nutrition and environmental responsibility. Algal oil capsules are now widely available in drugstore private-label ranges, while ingredient suppliers are introducing higher-potency algal oils, such as dsm-firmenich's life'sDHA B54-0100, launched in October 2024 with 545 mg DHA and 80 mg EPA per gram, enabling smaller capsules and gummy formats. The continued expansion of the EU Union list of authorized algal oils, including Schizochytrium sp. (CABIO-A-2) oil in July 2024 and corrections to the conditions of use for Schizochytrium sp. oil rich in DHA and EPA in July 2025, is broadening the range of approved suppliers. German companies are also at the forefront of high-concentration and pharmaceutical-grade omega-3 production through KD Pharma's Bexbach facility. The growing emphasis on sustainability, traceability, and reduced reliance on wild fish is expected to continue driving demand for algal and certified marine oils.Policies• EU Food Supplements Directive and NemV Notification: Food supplements containing EPA and DHA are regulated under Directive 2002/46/EC and the German Food Supplements Ordinance (NemV). Manufacturers and importers must notify the BVL before placing products on the market, and products must comply with composition, labelling, and safety requirements enforced by the federal states' food control authorities.• EU Nutrition and Health Claims Regulation: Health claims for EPA and DHA are governed by Regulation (EC) No. 1924/2006 and Regulation (EU) No. 432/2012, which authorize claims for normal heart function, maintenance of normal blood triglyceride levels and blood pressure, and DHA contributions to normal brain function, vision, and maternal and infant development, each subject to specified intake conditions.• Infant Formula DHA Requirement: Under Delegated Regulation (EU) 2016/127, infant formula and follow-on formula must contain DHA at 20–50 mg per 100 kcal, making Germany a stable market for high-purity fish oil and algal DHA used in formula production.• Novel Food Authorization: Krill oil and algal oils require authorization under Regulation (EU) 2015/2283 and must be listed in the Union list of novel foods with specified conditions of use.

Schizochytrium sp. (CABIO-A-2) oil was authorized through Implementing Regulation (EU) 2024/2101 in July 2024, and Implementing Regulation (EU) 2025/1549 corrected the conditions of use for Schizochytrium sp. oil rich in DHA and EPA in July 2025.• BfR Risk Assessment and Maximum Level Recommendations: The BfR provides scientific risk assessments on food supplements, including recommended maximum daily amounts of EPA and DHA, which inform product formulation and enforcement by food control authorities in the absence of harmonized EU maximum levels.Segment AnalysisGermany EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within Germany, particularly in infant formula, prenatal supplements, and cognitive and eye health products. DHA is mandatory in infant formula under Delegated Regulation (EU) 2016/127, and algal DHA is increasingly used in vegan and prenatal supplements.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in Germany, driven by increasing interest in high-EPA concentrates for cardiovascular health, triglyceride management, mood support, and inflammation-related wellness. Germany is also a key production location for pharmaceutical-grade EPA concentrates through KD Pharma's Bexbach facility.Germany EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in Germany due to its cost-effectiveness and dominance in drugstore private labels. Fish oil is derived primarily from anchovy, sardine, and mackerel, with growing emphasis on MSC and Friend of the Sea certification.• Algae Oil represents the fastest-growing source category in Germany, driven by strong vegan and flexitarian demand, infant formula use, and the expanding range of EU-authorized algal oils. Evonik's Veramaris joint venture and dsm-firmenich's life'sDHA portfolio are key suppliers.• Krill Oil is a premium source category positioned for absorption and smaller capsule size, sold mainly through pharmacies and online channels. Krill supply has been affected by the early closures of the Antarctic krill fishery in 2025 and 2026.• Other Marine Sources hold a niche position in the German market, including cod liver oil, salmon oil, and calanus oil, primarily used in traditional supplements and pet nutrition.Germany EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in Germany, distributed through drugstores, pharmacies, supermarkets, discounters, and online platforms.

Omega-3 is among the most widely purchased supplements, supported by EU-authorized health claims.• Infant Formula represents a strategically important application segment, with DHA mandatory in all infant and follow-on formulas. Births fell to 654,241 in 2025, the lowest level since the postwar period, but the mandatory requirement ensures stable per-unit demand.• Pharmaceuticals represent an important application segment, including prescription omega-3-acid ethyl esters for hypertriglyceridemia and pharmaceutical-grade omega-3 APIs produced in Germany for export.• Food & Beverages encompasses omega-3-enriched bread, spreads, dairy, eggs, and plant-based alternatives, with algal oil increasingly used in vegan products.• Clinical Nutrition & Medical Foods includes fish oil-based lipid emulsions for parenteral nutrition and enteral formulas used in hospitals, with Germany home to major clinical nutrition companies such as Fresenius Kabi and B. Braun.• Pet Nutrition represents the fastest-growing application segment in Germany, supported by a pet market of almost EUR 7 billion in 2025 and 33.4 million dogs, cats, small mammals, and birds, according to IVH and ZZF. Cats, numbering 15.7 million, and dogs, numbering 10 million, are the main consumers of fish oil-enriched foods and supplements.Major EPA & DHA Manufacturers Operating in Germany• KD Pharma Group, Evonik (Veramaris), dsm-firmenich, Queisser Pharma (Doppelherz), Orthomol, Norsan, dm (Mivolis), Rossmann (Altapharma), Danone (Aptamil), HiPP, Nestlé, Fresenius Kabi, and B. Braun are leading players in the German EPA & DHA market, offering refined and concentrated fish oils, algal oils, finished supplements, DHA-fortified infant formula, and clinical nutrition products. KD Pharma Group completed its acquisition of dsm-firmenich's Marine Lipids business in October 2024.

Their strong presence, advanced refining and concentration technologies, scientific support programs, and established relationships with pharmacies, drugstores, and hospitals have driven adoption across the German market.• The market is also supported by contract manufacturers, private-label producers, ingredient distributors, and testing laboratories that provide formulation, encapsulation, and quality assurance support. With pharmaceutical-grade concentration capacity and a large, quality-conscious consumer base, Germany remains one of Europe's most important omega-3 markets.Germany EPA & DHA Supply and Pricing Economics• EPA and DHA products in Germany represent value-added nutritional products whose pricing depends on source, concentration, chemical form, certification, and channel. Pricing varies considerably between drugstore private labels, pharmacy brands, krill oil, and algal oil.• Refined fish oil prices spiked during the 2023–2024 El Niño disruption and normalized by late 2024, according to GOED, but the reduced 2026 Peruvian anchovy quota is expected to place renewed upward pressure on raw material prices.• Supplements are paid out-of-pocket, while prescription omega-3 medicines are reimbursed by statutory health insurance only for approved indications. Infant formula pricing reflects the mandatory DHA requirement and premium formulation.• Algal oil and krill oil command a premium over standard fish oil, while drugstore private labels exert continuous downward pressure on mass-market pricing.Market Outlook by Consumer Health Spending and Supply Infrastructure• Germany's EPA & DHA market growth is strongly linked to demographic aging, consumer health spending, and the strength of the drugstore and pharmacy channels, although private-label price competition and raw material volatility remain significant factors influencing profitability.• Private consumer spending drives the supplement and pet nutrition segments, while the mandatory DHA requirement in infant formula provides a stable demand base. Online pharmacies and drugstore e-commerce are expanding access to premium and specialty formats.• The future growth opportunity for EPA and DHA in Germany depends on sustained consumer trust in quality and sustainability, continued expansion of algal omega-3, the potential harmonization of EU maximum levels, and stronger integration of omega-3 within cardiovascular prevention and healthy aging. Germany's pharmaceutical-grade production capabilities and its role as a European hub for omega-3 innovation are expected to further support long-term market development.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.